Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA (K.I., S.S., S. Krishnan, T.B., S. Kianoush, J.A.-B., V.S.M., M.J.B.).
Department of Biostatistics, University of Washington, Seattle (J.L., R.L.M.).
Circ Cardiovasc Imaging. 2024 Sep;17(9):e016465. doi: 10.1161/CIRCIMAGING.123.016465. Epub 2024 Sep 17.
For individuals with a coronary artery calcium (CAC) score of 0, CAC rescans at appropriate timings are recommended, depending on individual risk profiles. Although nonalcoholic fatty liver disease, recently redefined as metabolic-associated fatty liver disease, is a risk factor for atherosclerotic cardiovascular disease events, its relationship with the warranty period of a CAC score of 0 has not been elucidated.
A total of 1944 subjects from the MESA (Multi-Ethnic Study of Atherosclerosis) with a baseline CAC score of 0, presence or absence of nonalcoholic hepatic steatosis, and at least 1 follow-up computed tomography scan were included. Nonalcoholic hepatic steatosis was defined using nonenhanced computed tomography and liver/spleen attenuation ratio <1. The association between nonalcoholic hepatic steatosis and new CAC incidence (CAC score >0) was evaluated using a Weibull survival model.
Nonalcoholic hepatic steatosis was identified in 268 (14%) participants. Participants with nonalcoholic hepatic steatosis had higher CAC incidence than those without nonalcoholic hepatic steatosis. Nonalcoholic hepatic steatosis was independently associated with new CAC incidence after adjustment for atherosclerotic cardiovascular disease risk factors (hazard ratio, 1.28 [95% CI, 1.05-1.57]; =0.015). Using a 25% testing yield (25% of participants with zero CAC at baseline would be expected to have developed a CAC score >0), the warranty period of a CAC score of 0 in participants with nonalcoholic hepatic steatosis was shorter than in those without nonalcoholic hepatic steatosis (4.7 and 6.3 years). This association was consistent regardless of sex, race/ethnicity, age, and 10-year atherosclerotic cardiovascular disease risk.
Nonalcoholic hepatic steatosis had an impact on the warranty period of a CAC score of 0. The study suggests that the time period until a CAC rescan should be shorter in those with nonalcoholic hepatic steatosis and a CAC score of 0.
对于冠状动脉钙(CAC)评分为 0 的个体,根据个体风险状况,建议在适当的时间进行 CAC 复查。尽管非酒精性脂肪性肝病(最近重新定义为代谢相关脂肪性肝病)是动脉粥样硬化性心血管疾病事件的危险因素,但它与 CAC 评分为 0 的保证期之间的关系尚未阐明。
共纳入 1944 名基线 CAC 评分为 0、存在或不存在非酒精性肝脂肪变性且至少有 1 次随访计算机断层扫描的 MESA(动脉粥样硬化多民族研究)参与者。非酒精性肝脂肪变性使用非增强计算机断层扫描和肝/脾衰减比<1 定义。使用 Weibull 生存模型评估非酒精性肝脂肪变性与新 CAC 发生率(CAC 评分>0)之间的关系。
268 名(14%)参与者存在非酒精性肝脂肪变性。与无非酒精性肝脂肪变性的参与者相比,有非酒精性肝脂肪变性的参与者 CAC 发生率更高。在校正动脉粥样硬化性心血管疾病危险因素后,非酒精性肝脂肪变性与新 CAC 发生率独立相关(风险比,1.28[95%CI,1.05-1.57];=0.015)。使用 25%的检测结果(预计 25%的基线 CAC 评分为 0 的参与者会出现 CAC 评分>0),非酒精性肝脂肪变性患者 CAC 评分为 0 的保证期短于无非酒精性肝脂肪变性的患者(4.7 年和 6.3 年)。这种关联在性别、种族/民族、年龄和 10 年动脉粥样硬化性心血管疾病风险方面是一致的。
非酒精性肝脂肪变性对 CAC 评分为 0 的保证期有影响。该研究表明,对于 CAC 评分为 0 且有非酒精性肝脂肪变性的患者,进行 CAC 复查的时间间隔应更短。